|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to clarify the expression and correlation of p-p62 and nuclear Nrf2 and their association with radioresistance in ESCC.
|
31755241 |
2020 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blocking glycolysis transiently inhibits cell proliferation and may therefore have therapeutically beneficial effects on NRF2<sup>high</sup> ESCC in humans.
|
30409900 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Nrf2-neutralizing antibody effectively reversed the TUG1 overexpression-mediated promotion of ESCC cell resistance to DDP.
|
31287493 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Positive Nrf2 expression in the nucleus was of diagnostic value for predicting ESCC from normal esophageal mucosae, and was significantly associated with poorer clinical response and poor progression-free survival after CRT.
|
29675925 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, strategies are proposed to target the NRF2 signaling pathway for therapy of NRF2<sup>high</sup> ESCC.
|
29752726 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TP53 and CDKN2A and copy number alterations in 11q (contains CCND1), 3q (contains SOX2), 2q (contains NFE2L2), and 9p (contains CDKN2A) were considered to be trunk variants; these were dominant mutations detected at high frequencies in clones of paired IEN and ESCC samples.
|
28365443 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, <i>miR-432-3p</i> was overexpressed in primary ESCC tumors (55 of 84, 65.5%) and a negative correlation between the expression level of KEAP1 and <i>miR-432-3p</i> in primary ESCC tumors was observed.<b>Implications:</b> These findings provide novel insights into the mechanism of NRF2 stabilization in human cancers.<i></i>.
|
28760781 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mutations were validated in several genes, including in TP53, CDKN2A, FAT1, NOTCH1, PIK3CA, KMT2D and NFE2L2, which had been previously implicated in ESCC.
|
26900290 |
2016 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our team found the expression of Nrf2 correlated with the lymph node metastasis of esophageal squamous cell carcinoma by pathological sections of esophageal carcinoma patients.
|
24028437 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, these findings reveal that miRNA-based therapy is effective against NRF2-stabilized ESCC tumors.
|
24307696 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genetic landscape of esophageal squamous cell carcinoma.
|
25151357 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Another three genes, NFE2L2, PTCH1 and NOTCH1, are mutated in ESCC only.
|
24724606 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified eight significantly mutated genes, of which six are well known tumour-associated genes (TP53, RB1, CDKN2A, PIK3CA, NOTCH1, NFE2L2), and two have not previously been described in ESCC (ADAM29 and FAM135B).
|
24670651 |
2014 |